GLP-1 Medications, Depression, and Anxiety: What the Evidence Shows

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited · Author: FormBlends Editorial

Key Takeaways

• FDA and EMA reviews in 2024 found no causal link between GLP-1 medications and increased suicidal ideation or depression at population level
• Wegovy label maintains a precautionary warning about monitoring for psychiatric changes, inherited from concerns raised by earlier obesity medications
• Patient-reported mood effects are mixed: many report improvement (often weight-loss-mediated), some report worsening (often during dose escalation or in vulnerable subgroups)
• Direct CNS effects on mood are biologically plausible but not clinically established; GLP-1 is not FDA-approved as an antidepressant
• SSRI and other antidepressant combination with GLP-1 is generally safe; no major drug-drug interactions

Direct answer

GLP-1 medications have a mixed relationship with mood. The FDA and EMA conducted formal reviews in 2024 after post-marketing reports of suicidal ideation and depression on semaglutide and tirzepatide; both agencies concluded the available data did not establish a causal link. Patient-reported mood changes occur in both directions, with weight-loss-mediated improvement most common but some patients reporting new or worsening symptoms during treatment. No GLP-1 medication is FDA-approved as an antidepressant or anxiolytic. The signal is interesting and worth monitoring, but not strong enough to recommend GLP-1 medications for mood indications.

Table of contents

1. The post-marketing signal that started the conversation
2. The 2024 FDA and EMA reviews
3. What the controlled trials show about mood
4. The weight-loss-mediated effect
5. Plausible direct CNS mechanisms
6. Anxiety: a more complicated picture
7. Antidepressant drug interactions
8. Eating disorder considerations
9. The contrary view: why caution remains reasonable
10. Decision framework
11. FAQ
12. Sources

The post-marketing signal that started the conversation

In July 2023, the Icelandic Medicines Agency reported that it had received case reports of suicidal ideation in patients taking GLP-1 medications (semaglutide and liraglutide). The European Medicines Agency (EMA) initiated a review.

The signal aligned with longer-standing concerns about obesity medications and psychiatric risk:

• Rimonabant (cannabinoid receptor antagonist for obesity): pulled from the European market in 2008 after suicidal ideation signals
• Sibutramine: pulled in 2010 after cardiovascular signals, with separate concerns about mood
• Naltrexone-bupropion (Contrave): carries a boxed warning about suicidality, inherited from the bupropion component
• Phentermine-topiramate (Qsymia): carries a warning about depression and suicidal ideation

The history of obesity medications having psychiatric problems made regulators sensitive to the GLP-1 signal even when the case numbers were small relative to the prescription base.

The 2024 FDA and EMA reviews

Both agencies conducted formal reviews and reported in 2024.

FDA review (April 2024):

• Reviewed FAERS (FDA Adverse Event Reporting System) data on suicidal ideation in GLP-1 users
• Reviewed available clinical trial data, including SELECT
• Conclusion: preliminary review did not show clear evidence that GLP-1 medications cause suicidal thoughts or actions
• Stated intent to continue monitoring and recommended that healthcare providers inform patients about possible psychiatric symptoms and monitor accordingly

EMA review (April 2024):

• Reviewed available pharmacovigilance and clinical trial data
• Conclusion: no causal association between GLP-1 medications and suicidal thoughts established
• Recommended labeling continue to advise monitoring, without strengthening warnings

Both reviews effectively de-escalated the safety concern without dismissing it. The labels did not gain stronger warnings; the existing monitoring guidance remained.

What the controlled trials show about mood

SELECT (Lincoff et al., NEJM 2023) is the largest controlled trial with extended psychiatric safety follow-up:

• 17,604 patients with established cardiovascular disease and overweight/obesity
• Semaglutide 2.4 mg weekly versus placebo
• Mean follow-up 3.3 years
• Suicidal ideation events: 0.4% semaglutide vs 0.4% placebo (no difference)
• Depression events: similar rates between arms
• Suicide attempts: rare in both arms, no difference

STEP 1 (Wilding et al., NEJM 2021) and STEP 4 (Rubino et al., JAMA 2021) included Patient Health Questionnaire-9 (PHQ-9) depression scores. Semaglutide groups showed modest improvement in PHQ-9 scores, mostly tracking weight loss.

SURMOUNT trial program (tirzepatide) showed similar patterns: no increase in psychiatric adverse events, mild improvement in mood scales tracking weight loss.

The trial data are reassuring on safety. They are mildly supportive of weight-loss-mediated mood improvement. They do not show a strong direct antidepressant effect.

The weight-loss-mediated effect

The simplest explanation for GLP-1-associated mood improvement is that weight loss improves mood in patients whose depression was tied to weight, body image, or weight-related medical conditions.

Pre-GLP-1 evidence supports this:

• Bariatric surgery patients show meaningful depression improvement post-operatively, with substantial weight loss as the mediator
• Lifestyle weight-loss interventions show modest depression score improvements correlated with weight loss magnitude
• Weight-related comorbidity reduction (joint pain, sleep apnea, diabetes) independently improves quality of life and mood

For GLP-1 patients, the weight-mediated effect is consistent across studies. PHQ-9 score improvements track weight loss magnitude. The strongest mood improvements occur in patients with the largest weight reductions.

For patients whose depression is not tied to weight (primary major depressive disorder, situational depression unrelated to body weight), the weight-mediated benefit is smaller. This is one reason why GLP-1 medications are not effective antidepressants in the general sense.

Plausible direct CNS mechanisms

Beyond weight-mediated effects, several biological pathways could connect GLP-1 to mood:

Neuroinflammation. The inflammation hypothesis of depression suggests that chronic low-grade inflammation contributes to depressive symptoms in a subset of patients. GLP-1 medications reduce systemic inflammation markers. Animal studies show GLP-1 reduces microglial activation in the brain. The clinical translation in humans is uncertain.

Insulin and glucose effects. Insulin resistance is associated with elevated depression risk. Improving insulin sensitivity may improve mood through CNS metabolic effects. The "metabolic depression" subtype is being studied as a potential target for GLP-1 medications.

HPA axis modulation. The hypothalamic-pituitary-adrenal axis is dysregulated in depression. GLP-1 receptors are expressed in the hypothalamus and may affect cortisol regulation.

Reward signaling. The same mesolimbic mechanism that may affect addictive behaviors could affect anhedonia (loss of pleasure), a core feature of depression. Whether this is good or bad depends on the direction; if GLP-1 dampens reward signaling generally, it might worsen anhedonia in some patients.

BDNF and neuroplasticity. Some animal studies suggest GLP-1 increases brain-derived neurotrophic factor (BDNF), which is implicated in antidepressant response.

None of these mechanisms has been definitively translated to clinically meaningful antidepressant activity in humans. The mechanisms support hypothesis generation for future trials.

Anxiety: a more complicated picture

Anxiety effects on GLP-1 are less studied than depression. Patient reports describe both directions:

Anxiety reduction:

• Reduced food preoccupation eliminates a major source of distress for some patients
• Weight loss reduces social anxiety related to body image
• Improved metabolic markers reduce health-related anxiety
• Better sleep (from OSA improvement) reduces daytime anxiety

Anxiety increase:

• GI side effects (nausea, gastroparesis) can trigger or worsen anxiety in susceptible patients
• Rapid weight changes can produce body image or identity discomfort
• Social attention to weight loss can create anxiety
• Heart rate increase associated with some GLP-1 medications can mimic anxiety symptoms
• The dose escalation phase, with side effects emerging, is a common period for anxiety reports

Pre-existing anxiety disorders are not a contraindication to GLP-1 medications. Monitoring is reasonable, particularly during dose changes.

Antidepressant drug interactions

Most antidepressant classes can be safely combined with GLP-1 medications. Drug-specific notes:

Antidepressant class	GLP-1 interaction profile
SSRIs (sertraline, escitalopram, fluoxetine, etc.)	No significant interaction
SNRIs (venlafaxine, duloxetine)	No significant interaction; monitor blood pressure with combined use
Bupropion	No significant interaction; bupropion's metabolic neutrality is favorable
Mirtazapine	Mirtazapine's appetite stimulation may oppose GLP-1's appetite suppression
Tricyclics	Generally compatible; tricyclics can affect GI motility, potentially compounding with GLP-1 gastroparesis effects
MAOIs	No significant interaction
Lithium	GLP-1 may affect renal function modestly; lithium requires careful monitoring regardless
Antipsychotics (off-label for depression)	Some antipsychotics cause weight gain that opposes GLP-1's effect; metabolic monitoring useful

Bupropion is sometimes mentioned as a potentially advantageous antidepressant for patients on GLP-1 because it does not promote weight gain (some other antidepressants do). This is not a contraindication framework for other classes; weight effects of antidepressants are usually modest compared to GLP-1's effects.

Eating disorder considerations

The intersection of GLP-1 medications and depression/anxiety extends into eating disorder concerns. Eating disorders are commonly comorbid with depression and anxiety. GLP-1 effects on appetite and reward signaling interact with eating disorder pathology in complicated ways.

Considerations:

• Active anorexia nervosa: generally a contraindication for GLP-1 medications
• Active bulimia or binge eating disorder: more nuanced; some clinicians use GLP-1 for binge eating with monitoring, others avoid
• History of eating disorders: warrants careful evaluation before starting GLP-1, particularly in lean patients
• Body dysmorphic disorder: GLP-1 weight loss may not address underlying body image concerns and may worsen them in some cases

Mental health screening before GLP-1 initiation is becoming more common in 2026, particularly in telehealth settings where screening can be standardized.

The contrary view: why caution remains reasonable

Argument 1: Post-marketing surveillance has limits. Adverse event reporting captures only a fraction of real events. Even if the formal reviews did not establish causation, real psychiatric events on GLP-1 medications do occur in clinical practice. The labels appropriately maintain monitoring guidance.

Argument 2: Subgroups may differ from population averages. Population-level analyses smooth over individual variation. Some patients may be more vulnerable to mood effects (genetic predisposition, prior psychiatric history, current stressors). Aggregate "no signal" findings do not rule out individual harm.

Argument 3: Rapid weight loss has known psychological effects. Large rapid weight changes can produce identity, social, and body image disruptions. These are not specific to GLP-1 medications but apply to any intervention producing substantial weight loss.

Argument 4: The "reduced food noise" effect cuts both ways. For patients whose relationship with food is central to their identity or coping, the loss of that relationship can be disorienting and depressing. The reduction in food preoccupation that helps many patients is not universally welcome.

Argument 5: Long-term mood data are limited. Most trials report mood at 52-72 weeks. Longer-term effects on mood, particularly during weight regain after discontinuation, are not well characterized.

Decision framework

If you have depression and obesity: GLP-1 medications for the obesity indication may produce modest mood improvement through weight loss. They are not antidepressants and should not replace appropriate mental health treatment.

If you have depression without obesity: GLP-1 medications are not indicated for depression alone. Standard antidepressant treatment is first-line.

If you have anxiety and considering GLP-1: Anxiety is not a contraindication. Monitor during dose escalation. Some patients improve, some worsen, most see little change in anxiety symptoms.

If you have a history of eating disorders: Discuss with both a GLP-1 prescriber and an eating disorder specialist. Some patients can safely use GLP-1 medications with monitoring; others should not.

If you develop new depressive symptoms on GLP-1: Talk to your prescriber promptly. Evaluation may include mental health consultation, dose adjustment, or treatment continuation with closer monitoring depending on severity.

If you have suicidal thoughts on GLP-1 (or otherwise): Seek immediate care. Call 988 (Suicide and Crisis Lifeline) or go to the emergency department. Medication concerns can be sorted out after acute safety is addressed.

FAQ

Do GLP-1 medications cause depression?

FDA and EMA 2024 reviews did not establish a causal link. Post-marketing reports of mood changes occur but population-level rates are not elevated.

Can GLP-1 medications help depression?

Modest mood improvement is common, mostly weight-loss-mediated. No GLP-1 is FDA-approved as an antidepressant.

What did SELECT show about mood?

Psychiatric event rates were similar between semaglutide and placebo over 3.3 years. Supports the conclusion of no increased risk.

What about anxiety?

Mixed reports. Some patients see reduction, some increase, most see little change. Not a contraindication; monitor during dose escalation.

Could GLP-1 have direct brain effects on mood?

Plausible based on receptor distribution and mechanism. Not clinically established. Hypothesis-generating only.

Should I stop GLP-1 if I feel depressed?

Talk to your prescriber. Mild symptoms with monitoring may not require discontinuation. Significant symptoms or suicidal thoughts require immediate evaluation.

Can I take GLP-1 with an SSRI?

Generally yes. No major interactions with SSRIs or most other antidepressants.

Why does the Wegovy label mention suicidal thoughts?

Precautionary post-marketing surveillance language. The FDA and EMA 2024 reviews did not establish causation; the warning persists as monitoring guidance.

Does GLP-1 worsen anhedonia?

Possibly for some patients. The reward-signaling dampening that reduces food noise may extend to other previously pleasurable activities in vulnerable subgroups. Most patients do not report this.

What about bipolar disorder?

No specific contraindication, but mood stability monitoring is sensible. GLP-1 effects on weight (often elevated in bipolar patients due to antipsychotic medications) may be useful but should be coordinated with the patient's psychiatric care.

What if my antidepressant causes weight gain?

Combination with GLP-1 may help. The antidepressant addresses the mood; GLP-1 addresses the metabolic side effect. Discuss with both prescribers.

How do I monitor mood while on GLP-1?

Pay attention to changes in sleep, appetite (apart from medication-related changes), interest, energy, and concentration. PHQ-9 self-screening is freely available online. Talk to your prescriber if you notice changes.

Related guides

• GLP-1 Medications for PCOS: What the Evidence Actually Shows
• Can Wegovy Cause Depression? The Clinical Evidence Shows the Opposite Pattern
• Has Anyone Gotten Cancer from Ozempic? The Clinical Evidence on GLP-1 Medications and Cancer Risk
• GLP-1 Medications for MASH and Fatty Liver: The Evidence Map
• GLP-1 Medications for Sleep Apnea: The SURMOUNT-OSA Evidence
• GLP-1 Medications and Alcohol Use Disorder: The Emerging Evidence

Sources

1. FDA Statement. Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking GLP-1 receptor agonists. April 2024.
2. European Medicines Agency. Review of suicidal thoughts and self-injury with GLP-1 receptor agonists. April 2024.
3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). NEJM. 2023.
4. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
5. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021.
6. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
7. FDA Drug Label. Wegovy (semaglutide) Prescribing Information. Updated 2024.
8. FDA Drug Label. Zepbound (tirzepatide) Prescribing Information. Updated 2024.
9. Faulconbridge LF et al. Depression and weight loss intervention. Obesity. 2018.
10. Mansur RB et al. Inflammation and depression: pathophysiology and treatment. Translational Psychiatry. 2022.
11. Diz-Chaves Y et al. Anti-inflammatory effects of GLP-1 receptor activation in the central nervous system. Review. 2020.
12. National Institute of Mental Health. Suicide Prevention. 988 Suicide and Crisis Lifeline.

Footer disclaimers

Platform Disclaimer. FormBlends provides educational content. Mental health concerns require specialized care. If you are experiencing new or worsening mood symptoms, suicidal thoughts, or significant anxiety on any medication, contact your prescriber or a mental health professional promptly. Crisis: call or text 988 (Suicide and Crisis Lifeline) or go to an emergency department.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by state-licensed 503A compounding pharmacies pursuant to individual prescriptions. Compounded medications are not interchangeable with brand-name products.

Results Disclaimer. Mood effects of GLP-1 medications vary substantially by individual. Trial data describe population averages and primary endpoints. Patient-reported experiences are heterogeneous. Statements about mechanism are hypothesis-generating, not established clinical facts.

Trademark Notice. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Antidepressant brand names belong to their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.